Linaprazan

Linaprazan

Linaprazan

Pharmaceutical molecule

Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB).[1][2] Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.[3]

Quick Facts Clinical data, Other names ...

The drug was then licensed to Cinclus Pharma,[4] which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer biological half-life than linaprazan itself.[4]

Chemical structure of linaprazan glurate

References

  1. [1]
    Rawla P, Sunkara T, Ofosu A, Gaduputi V (December 2018). "Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?". World Journal of Gastrointestinal Pharmacology and Therapeutics. 9 (7): 63–68. doi:10.4292/wjgpt.v9.i7.63. PMC 6305499. PMID 30595950.
  2. [2]
    "Linaprazan". Inxight Drugs. National Center for Advancing Translational Sciences.
  3. [3]
    Tong A (4 March 2020). "Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes". endpts.com.
  4. [4]
    "Linaprazan glurate". Cinclus Pharma.
Share this article:

This article uses material from the Wikipedia article Linaprazan, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.